Bio-Techne Corporation is a global life sciences company providing tools and bioactive reagents for the research and clinical diagnostic communities. The Company's products assist scientific investigations into biological processes and the nature and progress of specific diseases. The Company, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex Bioreactors. Its segments include Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, and tissue biopsy analysis.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 68.69%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 68.69%.
Overvalued
The company’s latest PE is 133.17, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 161.69M shares, decreasing 4.59% quarter-over-quarter.
Held by Wallace Weitz
Star Investor Wallace Weitz holds 802.15K shares of this stock.